MX2020004543A - Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. - Google Patents

Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.

Info

Publication number
MX2020004543A
MX2020004543A MX2020004543A MX2020004543A MX2020004543A MX 2020004543 A MX2020004543 A MX 2020004543A MX 2020004543 A MX2020004543 A MX 2020004543A MX 2020004543 A MX2020004543 A MX 2020004543A MX 2020004543 A MX2020004543 A MX 2020004543A
Authority
MX
Mexico
Prior art keywords
methods
immunogenic compositions
same
zika
zika vaccines
Prior art date
Application number
MX2020004543A
Other languages
English (en)
Inventor
Jill A Livengood
Hansi Dean
Raman Rao
Jackie Marks
Htay Htay Han
Gary Dubin
Moerlooze Laurence De
Hetal Patel
Sushma Kommareddy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2020004543A publication Critical patent/MX2020004543A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

Vacunas contra el virus del Zika y composiciones inmunogénicas que tienen uno o más antígenos de un virus del Zika (por ejemplo, una forma aislada clonal del virus del Zika, un virus de Zica adaptado a células no humanas, etc.), y métodos de tratamientos y usos de las mismas.
MX2020004543A 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. MX2020004543A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059233 WO2019090238A1 (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Publications (1)

Publication Number Publication Date
MX2020004543A true MX2020004543A (es) 2020-09-18

Family

ID=64427224

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020004367A MX2020004367A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2020004542A MX2020004542A (es) 2017-11-03 2018-11-05 Metodo para inactivar el virus del zika y para determinar la inactivacion total.
MX2020004543A MX2020004543A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020004367A MX2020004367A (es) 2017-11-03 2018-11-05 Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2020004542A MX2020004542A (es) 2017-11-03 2018-11-05 Metodo para inactivar el virus del zika y para determinar la inactivacion total.

Country Status (12)

Country Link
US (5) US11730802B2 (es)
EP (3) EP3703740A2 (es)
JP (4) JP2021502350A (es)
KR (3) KR20200085302A (es)
CN (3) CN111615397A (es)
AU (6) AU2018359556B2 (es)
BR (3) BR112020008652A2 (es)
CA (3) CA3081586A1 (es)
MX (3) MX2020004367A (es)
MY (2) MY193736A (es)
SG (3) SG11202003796XA (es)
WO (3) WO2019090233A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090233A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
CA3137652A1 (en) * 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
EP4226155A1 (en) 2020-10-09 2023-08-16 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (zh) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 一种重组寨卡病毒减毒株及其制备方法和应用
CN112941201B (zh) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 一种用于多细胞种属鉴别和交叉污染检测的混合引物及其使用方法
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR102619184B1 (ko) * 2022-12-27 2023-12-29 주식회사 그린백스 에피갈로카테킨-3-갈레이트에 의해 불활화된 지카바이러스를 유효성분으로 포함하는 백신 조성물

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR100453132B1 (ko) 1996-12-20 2004-10-15 앨자 코포레이션 경피 약제 플럭스를 향상시키기 위한 장치 및 방법
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2382946T3 (es) 1997-08-28 2012-06-14 Cj Cheiljedang Corporation Virus de la encefalitis Japonesa atenuado
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
WO1999018221A1 (en) 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
CA2352457A1 (en) 1998-12-02 2000-06-08 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
WO2002083890A2 (en) 2000-11-22 2002-10-24 University Of Maryland, Baltimore Use of clya hemolysin for excretion of fusion proteins
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
US20080193478A1 (en) 2004-08-27 2008-08-14 Rajesh Jain Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
EP2578229B1 (en) 2004-09-09 2013-07-10 Novartis Vaccines and Diagnostics GmbH Decreasing potential iatrogenic risks associated with vaccine antigens
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
CN101516395B (zh) 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
CN101954076A (zh) 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
EA201391515A1 (ru) 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. Инактивированная вакцина вируса денге
WO2012172574A1 (en) 2011-06-17 2012-12-20 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
EP3106176B1 (en) 2011-12-06 2017-10-11 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
IN2013CH04135A (es) 2013-09-14 2015-08-14 Bharat Biotech Int Ltd
CN107002079A (zh) 2014-09-17 2017-08-01 衣阿华大学研究基金会 作为免疫调节剂和疫苗组分的病毒rna区段
CN106999569B (zh) 2014-10-07 2021-06-29 印度血清研究所私人有限公司 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3310382A4 (en) 2015-06-22 2019-01-02 President and Fellows of Harvard College Compositions and methods for modulating viral infection
UA126548C2 (uk) 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3355899A4 (en) 2015-09-30 2019-04-03 Ramot at Tel-Aviv University Ltd. In place of EVOLUTIONARY PRESERVED RNA STRUCTURE MUTATED APPROVED VIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP4218807A3 (en) 2015-12-23 2023-09-06 Valneva Austria GmbH Zika virus vaccine
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
EP3416683A1 (en) 2016-02-17 2018-12-26 CureVac AG Zika virus vaccine
CN115927399A (zh) 2016-02-25 2023-04-07 宾夕法尼亚大学理事会 新抗寨卡病毒疫苗
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
EP3454894B1 (en) 2016-05-10 2022-07-27 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
WO2017208191A1 (en) 2016-06-02 2017-12-07 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
WO2017214596A1 (en) 2016-06-09 2017-12-14 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating zika virus infection
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
EP3468590A1 (en) 2016-06-13 2019-04-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
JP7046848B2 (ja) 2016-07-08 2022-04-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 弱毒化突然変異体ジカウイルスをコードするゲノム配列
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
WO2018022786A1 (en) 2016-07-26 2018-02-01 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
EP4043031A3 (en) 2016-11-17 2022-11-23 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
US20190358313A1 (en) 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
CN108503697B (zh) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
CN108503696B (zh) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
EP3598865A4 (en) 2017-03-08 2021-04-07 University of Georgia Research Foundation, Inc. PROCEDURES AND COMPOSITIONS RELATED TO INCREASED VIRAL PRODUCTION
EP3606552A4 (en) 2017-04-07 2020-08-05 The Rockefeller University COMPOSITIONS AND PROCEDURES RELATED TO HUMAN NEUTRALIZING ANTIBODIES AGAINST ZIKA AND DENGUE-1 VIRUS
US11286502B2 (en) 2017-06-20 2022-03-29 Texas Tech University System ZIKA virus like particle (VLP) based vaccine and microneutralization assay
EP3417943B1 (de) 2017-06-21 2020-02-12 Eppendorf AG Zentrifugenrotor mit abdichtung
CN107188935B (zh) 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 一种寨卡病毒ns1抗原突变体及其应用
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN107537029B (zh) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 一种寨卡病毒与黄热病毒联合灭活疫苗
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2019090233A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
BR102017024030A2 (pt) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei Proteína recombinante imunogênica com antígenos de zika virus para vacina e seus usos
US20210054055A1 (en) 2017-11-21 2021-02-25 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
KR20200090893A (ko) 2017-11-30 2020-07-29 다케다 백신즈 인코포레이티드 지카 바이러스를 비활성화시키기 위한 방법, 및 관련 방법들
CN108187036A (zh) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗
CN108210921A (zh) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
WO2019162465A1 (en) 2018-02-22 2019-08-29 Nano4 Global, Lda Method for detecting flaviviridae
CN112040977A (zh) 2018-03-08 2020-12-04 科达金尼克斯有限公司 减毒黄病毒
JP2021519762A (ja) 2018-03-29 2021-08-12 イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ ワクチン組成物
KR102075581B1 (ko) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물
KR102253190B1 (ko) 2018-07-18 2021-05-18 (주)진매트릭스 지카 바이러스 변이주와 이를 포함한 지카 백신 조성물
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210308250A1 (en) 2018-10-26 2021-10-07 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CA3137652A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
WO2021262659A1 (en) 2020-06-22 2021-12-30 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
WO2019090228A3 (en) 2019-06-20
SG11202003800YA (en) 2020-05-28
AU2018359558C1 (en) 2022-09-22
US20200360505A1 (en) 2020-11-19
US20230414743A1 (en) 2023-12-28
AU2022209239B2 (en) 2023-10-05
EP3703740A2 (en) 2020-09-09
BR112020008665A2 (pt) 2020-11-10
JP2023175761A (ja) 2023-12-12
US20210177958A1 (en) 2021-06-17
CN111511395A (zh) 2020-08-07
JP2021505648A (ja) 2021-02-18
CN111615397A (zh) 2020-09-01
MX2020004542A (es) 2020-09-18
JP2021502350A (ja) 2021-01-28
AU2018359660B2 (en) 2022-02-24
KR20200085302A (ko) 2020-07-14
AU2018359558A1 (en) 2020-05-28
KR20200117981A (ko) 2020-10-14
AU2022203422B2 (en) 2023-10-05
MY193736A (en) 2022-10-27
CA3081586A1 (en) 2019-05-09
AU2018359556B2 (en) 2021-12-02
SG11202003949TA (en) 2020-05-28
AU2022201109B9 (en) 2022-05-12
BR112020008652A2 (pt) 2020-11-10
AU2022203422A1 (en) 2022-06-09
WO2019090238A1 (en) 2019-05-09
AU2018359660A1 (en) 2020-05-28
JP7295124B2 (ja) 2023-06-20
MX2020004367A (es) 2020-10-19
MY194449A (en) 2022-11-30
CA3081578A1 (en) 2019-05-09
US11964008B2 (en) 2024-04-23
JP2021502075A (ja) 2021-01-28
CN111526885A (zh) 2020-08-11
EP3703739A2 (en) 2020-09-09
BR112020008693A2 (pt) 2020-10-13
WO2019090233A3 (en) 2019-06-13
CA3081581A1 (en) 2019-05-09
SG11202003796XA (en) 2020-05-28
US20210177959A1 (en) 2021-06-17
JP7443232B2 (ja) 2024-03-05
AU2018359556A1 (en) 2020-05-28
EP3703741A1 (en) 2020-09-09
AU2022201109A1 (en) 2022-03-10
US20230145065A1 (en) 2023-05-11
US11478541B2 (en) 2022-10-25
WO2019090228A2 (en) 2019-05-09
US11648304B2 (en) 2023-05-16
WO2019090233A2 (en) 2019-05-09
AU2022201109B2 (en) 2022-04-28
AU2018359558B2 (en) 2021-12-02
AU2022209239A1 (en) 2022-08-18
US11730802B2 (en) 2023-08-22
KR20200083571A (ko) 2020-07-08

Similar Documents

Publication Publication Date Title
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
EA201800108A1 (ru) Вакцинные композиции для профилактики абровирусных инфекций
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112017001310A2 (pt) coronavírus
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
AR105470A1 (es) Métodos para inducir una respuesta inmune
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
AR101814A1 (es) Partícula de tipo virus flavivirus
PE20190397A1 (es) Virus de enteritis de pato y usos del mismo
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
CL2021001256A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470)
MA43517A (fr) Vaccin multivalent contre m. hyo et ses utilisations
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
AR104271A1 (es) Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas